by: Parent Project Muscular Dystrophy
REGENXBIO recently joined PPMD for a community webinar to provide an update on its AFFINITY DUCHENNE trial of RGX-202, REGENXBIO’s microdystrophin gene therapy. Dr. Naz Dastgir discussed the company’s pivotal trial plans and shared interim Phase I/II clinical data, including the first functional data for RGX-202. The webinar also included an extensive Q&A portion, during which Dr. Dastgir and REGENXBIO’s Chief Scientific Officer, Olivier Danos, PhD, answered questions from the audience.
